Objective-Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis. We investigated the molecular basis of the antiatherosclerotic effect of nifedipine in macrophages and apolipoprotein E-deficient mice. Methods and Results-In macrophages, nifedipine increased peroxisome proliferator-activated receptor-␥ (PPAR␥) activity without increasing PPAR␥-binding activity. Amlodipine, another L-type calcium channel blocker, and 1,2-bis-(oaminophenoxy)-ethane-N,N,-NЈ,NЈ-tetraacetic acid tetraacetoxy-methyl ester (BAPTA-AM), a calcium chelator, decreased PPAR␥ activity, suggesting that nifedipine does not activate PPAR␥ via calcium channel blocker activity. Inactivation of extracellular signal-regulated kinase 1/2 suppressed PPAR␥2-Ser112 phosphorylation and induced PPAR␥ activation. Nifedipine suppressed extracellular signal-regulated kinase 1/2 activation and PPAR␥2-Ser112 phosphorylation, and mutating PPAR␥2-Ser112 to Ala abrogated nifedipine-mediated PPAR␥ activation. These results suggested that nifedipine inhibited extracellular signal-regulated kinase 1/2 activity and PPAR␥2-Ser112 phosphorylation, leading to PPAR␥ activation. Nifedipine inhibited lipopolysaccharide-induced monocyte chemoattractant protein-1 expression and induced ATP-binding cassette transporter A1 mRNA expression, and these effects were abrogated by small interfering RNA for PPAR␥. Furthermore, in apolipoprotein E-deficient mice, nifedipine treatment decreased atherosclerotic lesion size, phosphorylation of PPAR␥2-Ser112 and extracellular signal-regulated kinase 1/2, and monocyte chemoattractant protein-1 mRNA expression and increased ATP-binding cassette transporter A1 expression in the aorta.
H ypertension is a major risk factor for atherosclerosis. 1, 2 However, the detailed mechanisms that link elevated blood pressure to progression of atherosclerosis remain unclear. Hypertension may promote the expression of cell adhesion molecules in endothelial cells 3 and production of cytokines in the vessel wall, 4 suggesting that hypertensive stress stimulates a proinflammatory response and contributes to the progression of atherogenesis. On the other hand, low-density lipoprotein (LDL) derived from hypertensive patients is more susceptible to lipid peroxidation mediated by angiotensin II and to its cellular uptake by macrophages than that obtained from normotensive subjects. 5 Therefore, monocyte-derived macrophages and macrophage-derived foam cells may accelerate atherosclerosis in hypertensive patients.
Massive clustering of macrophage-derived foam cells in the subendothelial spaces of arterial walls is a characteristic feature of early atherosclerotic lesions. 6 Monocytes subsequently adhere to the endothelial cells, cross the endothelial layer to enter the subendothelial space, differentiate into macrophages, and eventually become foam cells. Macro-phage-derived foam cells are characterized by the accumulation of cholesteryl esters resulting from the uptake of modified lipoproteins through macrophage scavenger receptors. Foam cells produce bioactive molecules, such as cytokines and growth factors, and contribute to the development and progression of atherosclerosis. 6 Calcium channel blockers (CCBs) are relevant treatments for patients with hypertension. Beyond causing vasodilatation by inhibiting calcium cannels, long-acting L-type CCBs produce clinical benefits in patients with coronary artery disease that might be independent of blood pressure changes. 7, 8 In fact, in vivo and in vitro studies demonstrated that L-type CCBs induce NO production in coronary microvessels 9 and inhibit smooth muscle cell (SMC) migration and proliferation. 10 Therefore, L-type CCBs may be antiatherogenic without their antihypertensive effects.
Peroxisome proliferator-activated receptor-␥ (PPAR␥) is a low-affinity dietary lipid receptor (reviewed by Rosen and Spiegelman in Reference 11 ). After binding to a ligand (eg, thiazolidinediones, arachidonate, 15-hydroxyeicosatetraenoic acid, or others), it forms a heterodimer with the cis-retinoic acid retinoid X receptor, binds to a PPAR response element, and activates gene transcription. PPAR␥ regulates gene expression in cell types that exist in atherosclerotic lesions, such as macrophages, 12 endothelial cells, 13 and vascular SMCs. 14 PPAR␥ has many antiatherogenic effects in these cells. 15 In addition, PPAR␥ agonists inhibit the development of atherosclerosis in LDL receptor-deficient mice 16 and in apolipoprotein E-deficient (apoE Ϫ/Ϫ ) mice. 17 Thus, PPAR␥ activation is beneficial for suppressing atherosclerosis.
Nifedipine, an L-type CCB, reduced the atherosclerotic plaque area in cholesterol-fed rabbits 18, 19 and suppressed the progression of atherosclerosis in hypertensive patients. 20 -24 However, the mechanism(s) of nifedipine-induced antiatherosclerotic activity are not fully understood. We wished to clarify whether the antiatherogenic effect of nifedipine is mediated by PPAR␥ activation. We revealed that nifedipine activates PPAR␥ through inactivating extracellular signalregulated kinase 1/2 (ERK1/2) and subsequently decreasing serine phosphorylation of PPAR␥ in macrophages. Moreover, nifedipine suppressed lipopolysaccharide (LPS)-induced monocyte chemoattractant protein-1 (MCP-1) expression and induced ATP-binding cassette transporter A1 (ABCA1) expression through PPAR␥ activation. Furthermore, nifedipine suppressed the progression of atherosclerosis in apoE Ϫ/Ϫ mice.
Methods

Materials
PD98059 and ciglitazone were purchased from Calbiochem. Nifedipine, fenofibrate, bezafibrate, and pioglitazone were kindly given from Bayer Yakuhin, Ltd., Kaken Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd., and Takeda Pharmaceutical, respectively. Amlodipine, 1,2-bis-(o-aminophenoxy)-ethane-N,N,-NЈ,NЈtetraacetic acid tetraacetoxy-methyl ester (BAPTA-AM) and U0126 were purchased from BIOMOL International, L.P. LPS (Escherichia coli O111:B4) was purchased from Sigma. Rabbit polyclonal anti-ERK1/2, anti-PPAR␥, anti-PPAR␥2 and anti-phospho PPAR␥2 antibodies, and goat polyclonal anti-␤-actin antibody were purchased from Santa Cruz Biotechnology, Inc. Rabbit polyclonal anti-phospho ERK1/2 antibody was purchased from Cell Signaling Technology. Rabbit polyclonal anti-ABCA1 antibody was purchased from Novus Biologicals, Inc. All other chemicals were of the best grade available from commercial sources.
Cell Culture
Peritoneal macrophages were collected from anesthetized male C3H/He mice (25 to 30 g body weight) by peritoneal lavage and were resuspended and incubated in medium A [RPMI medium 1640 (Nissui Seiyaku) supplemented with 10% FCS (Invitrogen Japan K.K.)/0.1 mg/mL streptomycin/100 U/mL penicillin]. 25, 26 More than 98% of the adherent cells were macrophages based on 4 criteria, as described previously. 27, 28 RAW264.7 cells were cultured in medium A in appropriate tissue culture plates as previously described. 29 THP-1 cells were cultured in medium A in 35-mm dishes and treated with 200 nmol/L of phorbol myristate acetate to induce their differentiation into macrophages. After 8 hours of incubation, the cells were washed twice with PBS and incubated in medium A until the initiation of experiments. 30 Animals, full-length PPAR␥ luciferase assay system, PPAR␥ GAL4 chimera assay system (measurement of PPAR␥ ligandbinding activity), luciferase assays, transcriptional activity of PPAR␥, transfection of small interfering RNA (siRNA) and plasmids, adenoviral vectors, cell transfection, Western blot analysis, reverse transcription and quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay for MCP-1, lipoprotein preparation, determination of cellular cholesterol content, and statistical analysis are described in the supplemental information, available online at http://atvb.ahajournals.org.
Results
Full-Length PPAR␥ Luciferase Assay System Is
Able to Measure PPAR␥ Activity RAW264.7 cells lack PPAR␥ expression. 12 To confirm whether RAW264.7 cells are suitable for our experiments, we first investigated the expression of PPAR␥ and the effect of the PPAR␥ agonists, ciglitazone and pioglitazone, on PPAR␥ activity using an (acyl-coenzyme A oxidase) 3 -luciferase [(AOX) 3 -luc] plasmid containing a PPAR response element of AOX. Expression of PPAR␥1 and PPAR␥2 proteins was confirmed by Western blot analysis in RAW264.7 cells, as well as in mouse peritoneal macrophages ( Figure 1A ). However, ciglitazone and pioglitazone increased the luciferase activity in mouse peritoneal macrophages ( Figure 1B ) but not in RAW264.7 cells ( Figure 1C ). Therefore, ligand-dependent PPAR␥ activation was not detectable in RAW264.7 cells transfected with (AOX) 3 -luc plasmids alone.
To construct a full-length PPAR␥ luciferase assay system, RAW264.7 cells were transfected with plasmid human cytomegalovirus X (pCMX)-PPAR␥2 and (AOX) 3 -luc. We then investigated luciferase activity using the PPAR␣ agonists, bezafibrate and fenofibrate, and the PPAR␥ agonists, ciglitazone and pioglitazone. Basal luciferase activity was 7-fold higher in cells overexpressing PPAR␥2 ( Figure 1C ). Moreover, 1 mol/L of ciglitazone and pioglitazone increased this luciferase activity, whereas 5 mol/L of fenofibrate and 5 mol/L of bezafibrate did not ( Figure 1C ). These results suggest that our full-length PPAR␥ luciferase assay system could selectively measure PPAR␥ activity.
Nifedipine Activates PPAR␥ in Macrophages
Nifedipine dose dependently (Ͻ1 nmol/L) increased luciferase activity in this same assay system ( Figure 2A ), with less activity at higher (10 nmol/L) levels. This activity was additive with pioglitazone or ciglitazone ( Figure 2B ), but nifedipine did not affect PPAR␥ ligand-binding activity ( Figure 2C ). These results suggest that nifedipine is not a direct ligand for PPAR␥, or it did not increase intracellular PPAR␥ ligands. Similar concentrations (1 nmol/L) of nifedipine increased PPAR␥ activity by 3.3-fold in mouse peritoneal macrophages (PϽ0.01 versus control) and 3.8-fold in THP-1 macrophages (PϽ0.01 versus control). Interestingly, amlodipine, another L-type CCB, decreased PPAR␥ activity ( Figure 2D ). BATPA-AM, an intracellular calcium chelator, also decreased PPAR␥ activity ( Figure 2E ).
Nifedipine Suppresses PPAR␥ Phosphorylation to Activate It
PPAR␥ activity is suppressed by mitogen-activated protein kinase-dependent phosphorylation. 31, 32 Mutating Ser112 to Ala within the putative ERK1/2 site in mouse PPAR␥2 (pCMX-PPAR␥2-S112A) abrogated ERK1/2-mediated inhibition of PPAR␥ activation. 32 We hypothesized that nifedipine suppressed ERK1/2 activation, thereby decreasing PPAR␥ phosphorylation and increasing PPAR␥ activation. Although nifedipine significantly increased luciferase activity in cells overexpressing wild-type PPAR␥2, nifedipine did not further enhance luciferase activity in cells overexpressing PPAR␥2-S112A ( Figure 3A ). Moreover, nifedipine dose dependently suppressed phosphorylation of PPAR␥2 in mouse peritoneal macrophages ( Figure 3B ) and in RAW264.7 cells overexpressing PPAR␥2 ( Figure 3C ).
Inactivation of ERK1/2 Is Involved in Nifedipine-Induced PPAR␥ Activation
The phosphorylation of Ser112 of PPAR␥2 is mediated by ERK1/2. 31, 32 Consistent with this finding, the MEK1/2specific inhibitor, PD98059, and dominant negative-ERK suppressed phosphorylation of PPAR␥2 in mouse peritoneal macrophages ( Figure 4A ). PD98059 also suppressed phosphorylation of PPAR␥2 in RAW264.7 cells expressing PPAR␥2 ( Figure 4B ). Moreover, PD98059 and the ERK1/2 inhibitor, U0126, increased PPAR␥ activity ( Figure 4C ) in RAW264.7 cells. Transfection of dominant negative-ERK also increased PPAR␥ activity ( Figure 4D ) in RAW264.7 cells, suggesting that ERK1/2 inhibition decreases PPAR␥ phosphorylation, leading to its activation. Nifedipine dose dependently blocked ERK1/2 phosphorylation in mouse peritoneal macrophages ( Figure 4E ) and RAW264.7 cells ( Figure  4F ). Moreover, overexpression of constitutively active MEKK enhanced phosphorylation of ERK1/2 in RAW264.7 cells, and nifedipine-mediated suppression of ERK1/2 phosphorylation was abrogated in these cells (supplemental Figure  IA) . Furthermore, PPAR␥ activation was suppressed in the cells overexpressed with constitutively active MEKK, and nifedipine-induced PPAR␥ activation was also abrogated in these cells (supplemental Figure IB) . These results suggest that the suppression of ERK1/2 by nifedipine is mainly involved in nifedipine-induced PPAR␥ activation.
Nifedipine Suppresses LPS-Induced MCP-1 Expression Through PPAR␥ Activation
LPS (1 g/mL) induced the expression of MCP-1 mRNA and protein in macrophages, and this expression was partially suppressed by nifedipine ( Figure 5A and 5B) . Pretreatment with PPAR␥ siRNA, which suppressed the expression of Figure 3 . Suppression of PPAR␥-Ser112 phosphorylation is involved in nifedipine-induced PPAR␥ activation. A, RAW264.7 cells were transfected with (AOX) 3 -luc and pCMX-PPAR␥2 [wild type (WT)] or pCMX-PPAR␥2-S112A (PPAR␥2-S112A) and were incubated with medium A in the absence or presence of 1 nmol/L nifedipine (Nife) for 24 hours. Luciferase activity was measured by Dual-Luciferase Reporter Gene Assay system. The data represent the meanϮSEM of 5 separate experiments. *PϽ0.01 vs control. B, Mouse peritoneal macrophages were incubated with medium A in the absence or presence of indicated concentration of nifedipine for 24 hours. Protein samples were immunoblotted with anti-phospho-PPAR␥2 or anti-PPAR␥2 antibodies. The data are representative of 4 experiments. C, RAW264.7 cells were transfected with pCMX-PPAR␥2 or mock, and then cells were incubated with medium A in the absence or presence of 1 nmol/L nifedipine for 24 hours. Protein samples were immunoblotted with anti-phospho-PPAR␥2 or anti-PPAR␥2 antibodies. The data are representative of 4 experiments. RLU indicates relative light unit. PPAR␥1 and PPAR␥2 by 76 and 82%, respectively ( Figure  5C ), restored the nifedipine-mediated suppression of MCP-1 mRNA and protein expression ( Figure 5A and 5B) . Moreover, U0126, as well as nifedipine, suppressed LPS-induced MCP-1 mRNA expression, and pretreatment with PPAR␥ siRNA restored these effects (supplemental Figure IIA) . These results suggest that nifedipine suppresses MCP-1 expression through inactivation of ERK1/2 and subsequently activation of PPAR␥.
Other reports indicate that MCP-1 expression is mediated by nuclear factor B (NF-B) activation. 33 In an NF-B-Luc luciferase assay system, LPS (1 g/mL) increased NF-B activity and nifedipine blocked this activation ( Figure 5D ). Treatment with siRNA for PPAR␥ restored nifedipinemediated suppression of NF-B activation ( Figure 5D ).
Nifedipine Induces ABCA1 Expression Through PPAR␥ Activation
The ABCA1, which is involved in the control of apoAImediated cholesterol efflux, is induced by PPAR␥ activation. 34 Here, nifedipine induced ABCA1 mRNA expression, as detected by real-time RT-PCR ( Figure 5E ), and this effect could be blocked by PPAR␥ siRNA (Figure 5E ). Western blot analysis also revealed that nifedipine increased ABCA1 protein expression ( Figure 5F ), and this effect was suppressed by PPAR␥ siRNA ( Figure 5F ). Moreover, U0126 also induced ABCA1 mRNA expression, and this effect was suppressed by pretreatment with PPAR␥ siRNA (supplemental Figure IIB) . We further examined the effect of nifedipine on oxidized LDL-induced foam cell formation and accumulation of cholesteryl esters in macrophages. Our results show that nifedipine had no effect on oxidized LDL-induced foam cell formation (supplemental Figure IIIA) and increase in the accumulation of cholesteryl esters (supplemental Figure IIIB) in macrophages.
Nifedipine Suppresses the Progression of Atherosclerosis in apoE ؊/؊ Mice through PPAR␥ Activation
Nifedipine treatment did not change body weight, systolic blood pressure, diastolic blood pressure, serum total cholesterol, triglyceride, or high-density lipoprotein cholesterol levels in apoE Ϫ/Ϫ mice (supplemental Table I ). However, nifedipine decreased the Oil Red O staining of atherosclerotic lesion in the aortic sinus ( Figure 6A and 6B) and whole aorta ( Figure 6A and 6C) . Western blot analysis of the aorta revealed that nifedipine decreased phosphorylation of both PPAR␥ and ERK1/2 ( Figure 6D ), and nifedipine also increased transcription of PPAR␥ in the aorta ( Figure 6E ). Nifedipine also blocked MCP-1 mRNA expression in the aortic sinus of apoE Ϫ/Ϫ mice ( Figure 6F ) but increased ABCA1 mRNA ( Figure 6G ) and protein ( Figure 6H ) levels.
Discussion
Several in vivo 18, 19 and clinical 20 -24 studies have indicated that nifedipine attenuates the formation of atherosclerotic lesions. However, the underlying mechanism has not been defined. Here, we revealed for the first time that nifedipine can induce PPAR␥ activation in macrophages between 1 pmol/L and 10 nmol/L, and the therapeutic concentrations of nifedipine (40 nmol/L) and amlodipine (3 nmol/L) were close to the concentrations of CCBs in in vitro study. Therefore, it is possible that nifedipine-mediated PPAR␥ activation appears to have potential physiological relevance. Moreover, nifedipine could enhance pioglitazone or ciglitazone-induced PPAR␥ activation. Thus, combination therapy with nifedi-pine and thiazolidinediones may help prevent atherosclerotic vascular diseases. Interestingly, amlodipine did not increase PPAR␥ activity, indicating that PPAR␥ activation is not a common effect of L-type CCBs. In addition, high-dose amlodipine and BATPA-AM reduced PPAR␥ activity, suggesting that decreases in intracellular calcium may mediate the suppression of PPAR␥ activity in macrophages. Our preliminary data indicated that nifedipine suppressed oxidized LDL-induced intracellular reactive oxygen species generation in macrophages, and this effect by nifedipine was higher than amlodipine (T. Matsumura et al, unpublished data). Moreover, one of the antioxidant reagents, N-(2-mercapto-procinyl)-glycine (NMPG) suppressed the phosphorylation of ERK1/2 and activated PPAR␥ in macrophages (T. Matsumura et al, unpublished data). Thus, it is possible that nifedipine-mediated antioxidative effect is mainly involved in PPAR␥ activation. Further studies are needed to clarify the involvement of reactive oxygen species generation on nifedipine-induced PPAR␥ activation. Nifedipine increased luciferase activity by full-length PPAR␥ but not by a PPAR␥ GAL4 chimera, indicating that nifedipine is not a direct PPAR␥ ligand and does not increase intracellular natural PPAR␥ ligands. ERK1/2 is an important protein kinase in the progression of atherosclerosis. 35 It has been reported that activating ERK1/2 phosphorylates PPAR␥ and downregulated its activity. 32 Here, specific inhibition of ERK1/2 suppressed PPAR␥ phosphorylation and increased PPAR␥ activity. In addition, nifedipine decreased PPAR␥ phosphorylation, but this was blocked in a mutant (S112A) PPAR␥ construct. Nifedipine also decreased ERK1/2 phosphorylation, which was also reported in ␣T3-1 cells and rat vascular SMCs, 36, 37 and constitutive activation of ERK1/2 abrogated nifedipineinduced PPAR␥ activation. These results suggested that the suppression of ERK1/2 by nifedipine is mainly involved in nifedipine-induced PPAR␥ activation. However, further studies are needed to clarify how nifedipine inhibits ERK1/2.
MCP-1 plays a critical role in recruiting monocytes into early atherosclerotic lesions, 38 because overexpression of MCP-1 in vessel wall macrophages led to increased foam cell formation and increased atherosclerosis. 39 Moreover, deletion of MCP-1 attenuated the progression of atherosclerosis in atherosclerotic models in mice. 40 Nifedipine suppresses angiotensin-II-induced MCP-1 expression through inhibiting NF-B in rat vascular SMCs. 41 Here, nifedipine suppressed LPS-induced MCP-1 expression and NF-B activation in macrophages, and siRNA for PPAR␥ attenuated these effects. Moreover, inactivation of ERK1/2 also suppressed LPSinduced MCP-1 expression, and siRNA for PPAR␥ attenuated these effects. Therefore, nifedipine may suppress NF-B-dependent MCP-1 expression through inactivation of ERK1/2 and subsequently PPAR␥ activation.
Nifedipine reduces atherosclerotic lesion areas in cholesterol-fed rabbits. 18, 19 Here, nifedipine suppressed the progression of atherosclerosis in apoE Ϫ/Ϫ mice, decreased phosphorylation of ERK1/2 and PPAR␥2, and activated PPAR␥ in the aortic sinus. Because PPAR␥ activators suppress the development of atherosclerosis in atherosclerotic models in mice, 16, 17 PPAR␥ activation may be critical for nifedipinemediated suppression of atherosclerosis.
ABCA1 is a member of the ABC transporter family and is involved in the control of apoAI-mediated cholesterol efflux from macrophages. 41 The activation of PPAR␥ induces ABCA1 expression in macrophages. 41 We revealed for the first time that nifedipine, as well as U0126, induced ABCA1 mRNA expression, and this effect was abrogated by siRNAs for PPAR␥, suggesting that nifedipine works via inactivation of ERK1/2 and subsequent PPAR␥ activation. Nifedipine significantly suppresses the acceleration of atherosclerosis and decreases cholesterol levels in aortic tissue in cholesterol-fed rabbits. 18 These changes may be mediated by PPAR␥-dependent increases in ABCA1 expression.
PPAR␥ agonists, including pioglitazone and rosiglitazone, improve insulin sensitivity and are now used for the treatment of type 2 diabetes. Because nifedipine can also activate PPAR␥, treatment with nifedipine may improve insulin sensitivity. In fact, nifedipine can increase insulin sensitivity in spontaneously hypertensive rats and diabetic rats. 42 Treatment with long-acting nifedipine improved insulin sensitivity in patients with hypertension 43 but did not affect insulin sensitivity in hypertensive obese patients. 44 Further research is necessary to determine the effectiveness of nifedipine on insulin resistance and diabetes.
In the present study, we revealed that the expression of PPAR␥1 and PPAR␥2 was detected in RAW264.7 cells by Western blot analysis. Moreover, we have reported that PPAR␥ mRNA was also expressed in RAW264.7 cells by real-time RT-PCR assay. 30 On the other hand, we revealed that PPAR␥ agonists did not increase the luciferase activity in RAW264.7 cells transfected with (AOX) 3 -luc plasmid alone, but they increased it in cells cotransfected with pCMV-PPAR␥2 and (AOX) 3 -luc plasmid. These results suggested that although the proteins were expressed in RAW264.7 cells, these proteins lack the transcriptional activity on the promoter that possesses peroxisome proliferator response element sequence. This may be due to the expression of abnormal PPAR␥1 and PPAR␥2 protein, which may lack ligand-binding activity or DNA-binding activity in RAW264.7 cells.
In conclusion, nifedipine, unlike amlodipine, activated PPAR␥ by decreasing phosphorylation of PPAR␥, thereby suppressing MCP-1 expression and inducing ABCA1 expression in macrophages. Moreover, nifedipine suppressed the acceleration of atherosclerosis in apoE Ϫ/Ϫ mice. These results could explain, at least in part, the effectiveness of nifedipine, unlike amlodipine, in hypertensive patients as well as in patients with diabetes and hyperlipidemia that have atherosclerotic vascular diseases.
